注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Immix Biopharma Inc是一家临床阶段的生物制药公司。该公司正在开发一类用于肿瘤学和炎症的组织特异性疗法(TSTx)。该公司主要资产IMX-110正在美国和澳大利亚进行实体瘤的Ib/IIa期临床试验。IMX-110是一种带负电荷的TSTx,它同时通过一种多激酶抑制剂禁用耐药途径,并通过一种控制肿瘤微环境(TME)正常化技术的凋亡诱导剂诱导肿瘤细胞死亡。IMX-110正在美国和澳大利亚进行实体瘤临床试验。该公司的System Multi-Action Regulators SMARxT Tissue-Specific平台生产的药物在预期治疗部位的积累速度是传统药物的三至五倍。其免疫正常化技术用于GLUT1抗体生物标志物靶向结合多酚聚激酶抑制剂/凋亡诱导剂的炎症性肠病。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Magda Marquet | 63 | 2021 | Independent Director |
Gabriel Morris | 36 | 2021 | CFO & Director |
Sant Chawla | - | - | Member of Scientific Advisory Board |
Helen C. Adams | 62 | 2021 | Independent Director |
Jane Melissa Buchan | 58 | 2021 | Independent Director |
Ilya Rachman | 50 | 2012 | Co-Founder, CEO & Chairman |
Yekaterina Chudnovsky | 38 | 2023 | Director |
Gary J. Schiller | - | - | Member of Scientific Advisory Board |
Razelle Kurzrock | - | - | Member of Scientific Advisory Board |
Jason Hsu | 48 | 2014 | Director |
Galit Lahav | - | 2021 | Member of Scientific Advisory Board |
Heather Landau | - | 2023 | Member of Scientific Advisory Board |
Michaela Liedtke | - | 2023 | Member of Scientific Advisory Board |
George W. Sledge | 71 | - | Member of Scientific Advisory Board |
Larry Norton | 76 | - | Member of Scientific Advisory Board |
Carey J. Ng | 44 | 2019 | Independent Director |
Suzanne Lentzsch | - | 2023 | Member of Scientific Advisory Board |
Marko Radic | - | 2023 | Member of Scientific Advisory Board |
Vaishali Sanchorawala | - | - | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核